
Reuters chief executive joins Pfizer board
pharmafile | July 2, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Pfizer, james smith, reuters
Pfizer has appointed the chief executive of information and media giant Thomson Reuters to its board of directors.
James Smith joins the firm immediately and has also been appointed to its corporate governance and science and technology committee.
Smith is the president and chief executive of Thomson Reuters where he has served on its board of directors since January 2012. Prior to this he held various leadership positions there, including chief executive and chief operating officer (COO) of its professional division.
Pfizer chairman and chief executive Ian Read, says: “We are pleased to have Jim Smith join Pfizer’s board of directors. He brings leadership and operational and international business experience to Pfizer’s Board, and will be an excellent asset to the company.”
Prior to the acquisition of Reuters by Thomson, he served as COO of Thomson and president and chief executive of its learning’s academic and reference group.
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …

Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …






